首页膀胱肿瘤治疗及预后证据详情

Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis

原文: 2018 年 发布于 Clin Genitourin Cancer 浏览量:257次

作者: Cui Y. Chen H. Q. Chen J. B. Zeng F. Zu X. B. Ding J.

作者单位: The George Washington University School of Medicine, Washington, District of Columbia. Electronic address: andyhnguyen@att.net. The George Washington University School of Medicine, Washington, District of Columbia.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.13201/j.issn.1001-1420.2021.10.012

文献简介

The prognostic significance of E-cadherin expression in bladder cancer (BC) has been elevated for years, but published results remain controversial and inconsistent. We thus performed a systematic review and meta-analysis to determine the association between E-cadherin expression and BC prognosis. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases to identify eligible studies published until March 2017. On the basis of our inclusion and exclusion criteria, a total of 2,089 patients from 19 studies were eligible for final analysis. Our results showed that reduced E-cadherin expression in BC was associated with poor overall survival (hazard ratio [HR] = 2.73, 95% CI: 1.74-4.27, p < 0.001), poor progression-free survival (HR = 6.39, 95% CI: 3.48-11.73, p < 0.001), and poor recurrence-free survival (HR = 2.48, 95% CI: 1.68-3.64, p < 0.001). Moreover, reduced E-cadherin expression was significantly correlated with pathological T stage (T2-4 vs. Ta-1: risk ratio [RR] = 2.14, 95% CI: 1.70-2.71), metastasis (yes vs. no: RR = 1.68, 95% CI: 1.17-2.40), grade (3 vs. 1/2: RR = 1.58, 95% CI: 1.29-1.93), and carcinoma in situ (yes vs. no: RR = 1.68, 95% CI: 1.09-2.58). This meta-analysis suggested that reduced E-cadherin expression was associated with poor prognosis and advanced clinicopathological characteristics and can serve as a useful biomarker for the clinical management of BC.

热门文献